Article Versions Notes

Keshtvarz M, Mahboobi M, Kieliszek M, Miecznikowski A, Sedighian H, Rezaei M, Haghighi MA, Zareh Z, Rezaei E. Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. Toxins. 2021; 13(11):785. https://doi.org/10.3390/toxins13110785

Keshtvarz, Maryam, Mahdieh Mahboobi, Marek Kieliszek, Antoni Miecznikowski, Hamid Sedighian, Milad Rezaei, Mohammad Ali Haghighi, Zahra Zareh, and Ehsan Rezaei. 2021. "Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study" Toxins 13, no. 11: 785. https://doi.org/10.3390/toxins13110785

Keshtvarz, M., Mahboobi, M., Kieliszek, M., Miecznikowski, A., Sedighian, H., Rezaei, M., Haghighi, M. A., Zareh, Z., & Rezaei, E. (2021). Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study. Toxins, 13(11), 785. https://doi.org/10.3390/toxins13110785